Nicole Beatrice Laferriere

Suggest Changes
Learn More
PURPOSE An open-label, phase II study to evaluate progression-free survival (PFS), overall best response, adverse events (AEs), and patient-reported outcomes with sorafenib versus interferon alfa-2a(More)